摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[[tert-butyl(dimethyl)silyl]oxymethyl]thiophene-3-carbonitrile | 913828-51-0

中文名称
——
中文别名
——
英文名称
5-[[tert-butyl(dimethyl)silyl]oxymethyl]thiophene-3-carbonitrile
英文别名
5-({[t-butyl(dimethyl)silyl]oxy}methyl)thiophene-3-carbonitrile
5-[[tert-butyl(dimethyl)silyl]oxymethyl]thiophene-3-carbonitrile化学式
CAS
913828-51-0
化学式
C12H19NOSSi
mdl
——
分子量
253.44
InChiKey
BONAZYQWRVNHIG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.14
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    61.3
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist
    摘要:
    S1P(3)-sparing S1P(1) agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC50 value of 4.0 nM for human S1P(1) and over 5000-fold selectivity against S1P(3). The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID50 value was determined at 0.407 mg/kg. The docking studies of CS-2100 with the homology model of S1P(1) and S1P(3) showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P(3), not in the case of Leu276 in S1P(1). This observation gives an explanation for the excellent S1P(3)-sparing characteristic of CS-2100. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.12.019
  • 作为产物:
    描述:
    4-溴-2-噻吩甲醛咪唑 、 sodium tetrahydroborate 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 生成 5-[[tert-butyl(dimethyl)silyl]oxymethyl]thiophene-3-carbonitrile
    参考文献:
    名称:
    Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist
    摘要:
    S1P(3)-sparing S1P(1) agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC50 value of 4.0 nM for human S1P(1) and over 5000-fold selectivity against S1P(3). The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID50 value was determined at 0.407 mg/kg. The docking studies of CS-2100 with the homology model of S1P(1) and S1P(3) showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P(3), not in the case of Leu276 in S1P(1). This observation gives an explanation for the excellent S1P(3)-sparing characteristic of CS-2100. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.12.019
点击查看最新优质反应信息

文献信息

  • GUANICIDE COMPOUND AND FUNGICIDE
    申请人:Nippon Soda Co., Ltd.
    公开号:US20180146677A1
    公开(公告)日:2018-05-31
    A novel guanidine compound having excellent fungicidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R 7 -R 9 independently represents a hydrogen atom or the like) or the like; each of X and Z independently represents an unsubstituted or substituted alkylene group or the like; each of Q 1 and Q 2 independently represents a single bond or the like; each of A 1 and A 2 independently represents an unsubstituted or substituted divalent heterocyclic compound residue or the like; and each of R 1 -R 6 independently represents a hydrogen atom or the like.)
    一种具有优异杀菌活性的新型啉化合物由式[I]表示。(在该式中,Y代表由式[II]表示的二价基团(其中R7-R9中的每一个独立地表示氢原子或类似物)或类似物;X和Z中的每一个独立地表示未取代或取代的烷基基团或类似物;Q1和Q2中的每一个独立地表示单键或类似物;A1和A2中的每一个独立地表示未取代或取代的二价杂环化合物残基或类似物;R1-R6中的每一个独立地表示氢原子或类似物。)
  • Heterocyclic compound
    申请人:Nishi Takahide
    公开号:US20080113961A1
    公开(公告)日:2008-05-15
    A compound having immunosuppressive activity with low toxicity or a pharmacological salt thereof. The compound has a general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof
    具有低毒性免疫抑制活性的化合物或其药理盐。该化合物具有下面所示的一般式(I)或其药理学上可接受的盐,或其药理学上可接受的前体。
  • 3-AZETIDINECARBOXYLIC ACID DERIVATIVES FOR USE AS IMMUNOSUPPRESSANTS
    申请人:Daiichi Sankyo Company, Limited
    公开号:EP1873153B1
    公开(公告)日:2010-07-07
查看更多